FDA’s shortage list today
Straight from FDA’s drug shortage database, last updated by FDA in October 2026.
- semaglutide: being discontinued (Rybelsus).
- tirzepatide: not on the list.
- liraglutide: in shortage (Liraglutide, Saxenda, Victoza); being discontinued (Liraglutide, Saxenda).
FDA drug shortage database · read through openFDA · discontinuation is a maker’s decision, not a shortage
In the regulator’s own words
"Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list."
"For a state-licensed pharmacy or physician compounding, dispensing or distributing semaglutide injection products under section 503A of the FD&C Act, the period of enforcement discretion (described below) has ended."
"Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
This page reports what the regulator has published, in its words. It is not legal or medical advice.



